Skip to main content

Research Repository

Advanced Search

All Outputs (2)

Transcriptomic and proteomic characterization of cell and protein biomarkers of checkpoint inhibitor-induced liver injury (2025)
Journal Article
Ji, C., Kumpf, S., Qian, J., Federspiel, J. D., Sheehan, M., Capunitan, D., Atallah, E., Astbury, S., Arat, S., Oziolor, E., Ocana, M. F., Ramaiah, S. K., Grove, J., Aithal, G. P., & Lanz, T. A. (2025). Transcriptomic and proteomic characterization of cell and protein biomarkers of checkpoint inhibitor-induced liver injury. Cancer Immunology, Immunotherapy, 74(6), Article 190. https://doi.org/10.1007/s00262-025-04033-z

Immune checkpoint inhibitors (ICI) targeting CTLA-4 and PD-1 have shown remarkable antitumor efficacy, but can also cause immune-related adverse events, including checkpoint inhibitor-induced liver injury (ChILI). This multi-omic study aimed to inves... Read More about Transcriptomic and proteomic characterization of cell and protein biomarkers of checkpoint inhibitor-induced liver injury.

The development of a food-group, tree classification method and its use in exploring dietary associations with Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) and other health-related outcomes in a UK Population (2025)
Journal Article
Alawadi, A. A., Vijay, A., Grove, J. I., Taylor, M. A., & Aithal, G. P. (2025). The development of a food-group, tree classification method and its use in exploring dietary associations with Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) and other health-related outcomes in a UK Population. Metabolism Open, 25, Article 100351. https://doi.org/10.1016/j.metop.2025.100351

Background
Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) affects up to one in five people in the UK, with persistent overeating and a sedentary lifestyle being significant risk factors. Exploring dietary patterns at a food level i... Read More about The development of a food-group, tree classification method and its use in exploring dietary associations with Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) and other health-related outcomes in a UK Population.